Cancer Center Support Grant

癌症中心支持补助金

• 批准号: 8533070
• 负责人: EDWARD J BENZ
• 金额: $ 7.5万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-10 至 2016-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8533070
• 关键词: Advanced Malignant Neoplasm; Award; Boston; Cancer Center; Cancer Center Support Grant; Clinical Research; Collaborations; Commit; Communities; Comprehensive Cancer Center; Conduct Clinical Trials; Country; Dana-Farber Cancer Institute; Development; Diagnosis; General Hospitals; Goals; Grant; Growth; Health Sciences; Hospitals; Institution; Israel; Lead; Leadership; Massachusetts; Medical center; Modeling; NCI-Designated Cancer Center; Pediatric Hospitals; Phase; Public Health Schools; Research; Research Infrastructure; Resource Sharing; Resources; Schools; Structure; Talents; Transcend; Vision; Woman; anticancer research; base; cancer prevention; forging; interest; medical schools; member; novel strategies; operation; patient population; programs; success

DESCRIPTION (provided by applicant): Now in its 12th year of operation, Dana-Farber/Harvard Cancer Center (DF/HCC) is the first consortium model, NCI-designated Comprehensive Cancer Center in the country. The consortium is comprised of 1,015 members from five principal Harvard-affiliated hospitals and two Harvard health science schools: Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital (BWH), Children's Hospital Boston (CHB), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Harvard School of Public Health (HSPH), and Massachusetts General Hospital (MGH). The progress presented in this proposal has required DF/HCC leadership, its combined resources, and, most importantly, its consortium structure. The overarching scientific vision is to unite the members. The research of the Center is carried out in Research Programs that cross both scientific and institutional boundaries. In addition, the Center supports Shared Resources dedicated to enhancing scientific efficiency available to all Center members. The unified clinical research infrastructure has made it easier for members to conduct clinical trials across the Center. Indirect indications of scientific progress are the substantial growth in the Center's gran portfolio, from $233 million in 1999 to $406 million in 2004, to $623 million in 2009, and the award of multiple translational grants that transcend organizational boundaries (e.g., SPOREs, SCORs, P01s, U01s, and SU2Cs). There is also an array of hypothesis-driven, Early Phase (pilot, I, I-II), and proof-of-concept trials, made possible through the development and execution of the Center, that are conducted daily across the consortium.

描述（由申请人提供）：目前在其运营的第12年中，达纳·法伯（Dana-Farber）/哈佛癌症中心（DF/HCC）是该国NCI指定的综合癌症中心的第一个财团模型。该财团由来自哈佛大学的五家主要医院和两所哈佛健康科学学校的1,015名成员组成：贝丝以色列女执事医疗中心（BIDMC），布里格姆和妇女医院（BWH），波士顿儿童医院（CHB），达纳 - 法伯尔伯癌研究所（DANA-FARBER CALSITUTE（DFCI），公共医疗学校（HMS），HMS，HOSCHARD（HMS）马萨诸塞州综合医院（MGH）。 该提案中提出的进展要求DF/HCC领导，其组合资源以及最重要的是其财团结构。总体科学愿景是团结成员。该中心的研究是在跨越科学和机构边界的研究计划中进行的。此外，该中心支持共享的资源，致力于提高所有中心成员可用的科学效率。统一的临床研究基础设施使成员更容易在中心进行临床试验。科学进步的间接迹象是该中心的Gran投资组合的实质增长，从1999年的2.33亿美元增加到2004年的4.06亿美元，至2009年的6.23亿美元，以及超越组织界限的多种翻译赠款奖励（例如，Spores，Spores，Scors，Scors，P01S，U01S，U01S和SU2C）。还有一系列由假设驱动的早期阶段（飞行员，I，I-II）和概念验证试验，这些试验通过该中心的开发和执行而成为可能，这些试验每天在整个财团中进行。